Compare PCT & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCT | COAG |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2020 | 2026 |
| Metric | PCT | COAG |
|---|---|---|
| Price | $6.08 | $39.22 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 286.6K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.86 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,355,000.00 | N/A |
| Revenue This Year | $380.44 | N/A |
| Revenue Next Year | $203.33 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.93 | $27.47 |
| 52 Week High | $15.49 | $55.42 |
| Indicator | PCT | COAG |
|---|---|---|
| Relative Strength Index (RSI) | 32.81 | 34.71 |
| Support Level | $5.75 | $28.51 |
| Resistance Level | $6.23 | $53.01 |
| Average True Range (ATR) | 0.33 | 3.60 |
| MACD | -0.05 | -0.98 |
| Stochastic Oscillator | 3.57 | 0.31 |
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.